Startups under new leadership

CodeCheck, Teralytics and ObsEva have strengthened their management team with new CEOs to support the companies on their internationalisation course. At Lunaphore, the team has expanded with a new Boardmember and VP sales member.

CodeCheck appoints CEO and CFO
With its app for evaluating products, CodeCheck has continued to empower consumers to buy the healthiest and most environmentally friendly products. The company seeks to internationalise its app with the support of the newly elected CEO, Gabriele Ottino, the former Doodle CEO. Ottino succeeds Boris Manhart, who together with the team made CodeCheck one of the most popular apps in the area of sustainability and health over the past six years. While at Doodle, Ottino supported the company in achieving international growth and a clear strategic focus on a long-term business model. He brings vast experience in strategy and product development as well as expertise in scaling an organisation that will enable him to transform CodeCheck into a global force for the future of conscious consumption.

In addition to the CEO CodeCheck has also appointed Christian Nauer, FS Partner AG to the position of CFO. Nauer, who as a data-oriented entrepreneur, has broad experience in growth and scaling. Nauer has been conducting due diligence on behalf of investors for over 15 years. In addition to focusing on the investor perspective, he aims to enhance reporting to reflect reality as realistically and promptly as possible and thus prepare CodeCheck for the next growth step.

Teralytics Dave Reed CEO
The mobility insights company built a platform to provide advanced mobility analytics powered by telecom network data, thereby help global transportation planners and mobility providers to create better, more sustainable journeys. The company has welcomed Dave to its team to lead the company in his new role as CEO. Reed joins Teralytics from MediaMath, where he oversaw the company’s global markets outside the US. Dave knows what it takes to exponentially scale a business while maintaining a sense of mission and purpose among a fast-growing team. Teralytics will benefit from his experience in bringing SaaS products to market, platform development and market expansion.

ObsEva Brian O’Callaghan
ObsEva is developing and commercialising novel therapies to improve women’s reproductive health and pregnancy. The company’s Board of Directors has appointed Brian O’Callaghan, to succeed Ernest Loumaye, as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. O’Callaghan is a Life Science Executive who brings a breadth of experience to ObsEva, having held senior positions within several public and private pharmaceutical and biotechnology companies, in both Europe and the United States. These include CEO positions at Petra Pharma, Acucela, Sangart and BioPartners, as well as senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals. He has also previously managed businesses and programs across multiple therapeutic areas - from concept through commercialisation, and as such is well qualified to leverage his significant experience to lead ObsEva through its future development, regulatory filings and product launches.

Lunaphore appoints new board member and VP Sales
John Marotta is the new Board member at Lunaphore and the President & CEO of Epredia, a PHC Group company (owned by KKR, as the largest shareholder) focused on anatomical pathology. Prior to joining Epredia, John’s most recent role was Senior Vice President of Supply Chain, Procurement, Real Estate, IT, Envista Business Systems and the LatAm region. He began his career at Johnson & Johnson operating companies, Janssen Pharmaceutica and DePuy Synthes Orthopaedics, where he held various commercial roles

Lunaphore also welcomes Everton Robinson as the new VP Sales. Robinson is an experienced International Commercial Business Leader with a proven track record of success in building multi-disciplinary commercial operations infrastructure for innovative and disruptive technology providers in the life science and diagnostic industry. He has joined Lunaphore from NanoString Technologies, where he was Director of EMEA Life Science and Diagnostic Sales Operations and established the EMEA commercial organisation from the ground up to 50 FTEs across all functional areas. Prior to NanoString, Robinson held various management positions at Illumina, ThermoFisher, Roche, Life Technologies,  achieving career revenues from $5M to >$120M.

Photo L-R: Gabriele Ottino and Christian Nauer (CodeCheck), Dave Reed (Teralytics), Brian O’Callaghan (Obseva),  John Marotta & Everton Robinson (Lunaphore)